Pfizer and BioNTech Announce Results from Vaccine Testing for Young Children

Pfizer and BioNTech announced favorable results from their three-dose COVID-19 vaccine for children ages 6 months to 5 years of age. This announcement comes nearly one month after Moderna shared a similar announcement on its two-dose COVID-19 vaccine for children ages 6 months to 6 years of age. Moderna submitted its trial results to the FDA on May 9, 2022, and it is likely that the Food and Drug Administration will review both Pfizer and Moderna’s data for emergency authorization in June.